Objectives: The long-term consequences of COVID-19 infection on the gastrointestinal tract remain unclear. Here, we aimed to evaluate the prevalence of gastrointestinal symptoms and post-COVID-19 disorders of gut-brain interaction after hospitalisation for SARS-CoV-2 infection. Design: GI-COVID-19 is a prospective, multicentre, controlled study. Patients with and without COVID-19 diagnosis were evaluated on hospital admission and after 1, 6 and 12 months post hospitalisation. Gastrointestinal symptoms, anxiety and depression were assessed using validated questionnaires. Results: The study included 2183 hospitalised patients. The primary analysis included a total of 883 patients (614 patients with COVID-19 and 269 controls) due to the exclusion of patients with pre-existing gastrointestinal symptoms and/or surgery. At enrolment, gastrointestinal symptoms were more frequent among patients with COVID-19 than in the control group (59.3% vs 39.7%, p<0.001). At the 12-month follow-up, constipation and hard stools were significantly more prevalent in controls than in patients with COVID-19 (16% vs 9.6%, p=0.019 and 17.7% vs 10.9%, p=0.011, respectively). Compared with controls, patients with COVID-19 reported higher rates of irritable bowel syndrome (IBS) according to Rome IV criteria: 0.5% versus 3.2%, p=0.045. Factors significantly associated with IBS diagnosis included history of allergies, chronic intake of proton pump inhibitors and presence of dyspnoea. At the 6-month follow-up, the rate of patients with COVID-19 fulfilling the criteria for depression was higher than among controls. Conclusion: Compared with controls, hospitalised patients with COVID-19 had fewer problems of constipation and hard stools at 12 months after acute infection. Patients with COVID-19 had significantly higher rates of IBS than controls. Trial registration number: NCT04691895.
Post COVID-19 irritable bowel syndrome / Marasco G.; Cremon C.; Barbaro M.R.; Cacciari G.; Falangone F.; Kagramanova A.; Bordin D.; Drug V.; Miftode E.; Fusaroli P.; Mohamed S.Y.; Ricci C.; Bellini M.; Rahman M.M.; Melcarne L.; Santos J.; Lobo B.; Bor S.; Yapali S.; Akyol D.; Sapmaz F.P.; Urun Y.Y.; Eskazan T.; Celebi A.; Kacmaz H.; Ebik B.; Binicier H.C.; Bugdayci M.S.; YaA Cl M.B.; Pullukcu H.; Kaya B.Y.; Tureyen A.; Hatemi A.; Koc E.S.; Sirin G.; Callskan A.R.; Bengi G.; Alls E.E.; Lukic S.; Trajkovska M.; Hod K.; Dumitrascu D.; Pietrangelo A.; Corradini E.; Simren M.; Sjolund J.; Tornkvist N.; Ghoshal U.C.; Kolokolnikova O.; Colecchia A.; Serra J.; MacOni G.; De Giorgio R.; Danese S.; Portincasa P.; Di Sabatino A.; Maggio M.; Philippou E.; Lee Y.Y.; Salvi D.; Venturi A.; Borghi C.; Zoli M.; Gionchetti P.; Viale P.; Stanghellini V.; Barbara G.. - In: GUT. - ISSN 0017-5749. - ELETTRONICO. - 0:(2022), pp. 328483.1-328483.9. [10.1136/gutjnl-2022-328483]
Post COVID-19 irritable bowel syndrome
Marasco G.;Barbaro M. R.;Cacciari G.;Fusaroli P.;Ricci C.;De Giorgio R.;Salvi D.;Borghi C.;Zoli M.;Gionchetti P.;Viale P.;Stanghellini V.;Barbara G.
2022
Abstract
Objectives: The long-term consequences of COVID-19 infection on the gastrointestinal tract remain unclear. Here, we aimed to evaluate the prevalence of gastrointestinal symptoms and post-COVID-19 disorders of gut-brain interaction after hospitalisation for SARS-CoV-2 infection. Design: GI-COVID-19 is a prospective, multicentre, controlled study. Patients with and without COVID-19 diagnosis were evaluated on hospital admission and after 1, 6 and 12 months post hospitalisation. Gastrointestinal symptoms, anxiety and depression were assessed using validated questionnaires. Results: The study included 2183 hospitalised patients. The primary analysis included a total of 883 patients (614 patients with COVID-19 and 269 controls) due to the exclusion of patients with pre-existing gastrointestinal symptoms and/or surgery. At enrolment, gastrointestinal symptoms were more frequent among patients with COVID-19 than in the control group (59.3% vs 39.7%, p<0.001). At the 12-month follow-up, constipation and hard stools were significantly more prevalent in controls than in patients with COVID-19 (16% vs 9.6%, p=0.019 and 17.7% vs 10.9%, p=0.011, respectively). Compared with controls, patients with COVID-19 reported higher rates of irritable bowel syndrome (IBS) according to Rome IV criteria: 0.5% versus 3.2%, p=0.045. Factors significantly associated with IBS diagnosis included history of allergies, chronic intake of proton pump inhibitors and presence of dyspnoea. At the 6-month follow-up, the rate of patients with COVID-19 fulfilling the criteria for depression was higher than among controls. Conclusion: Compared with controls, hospitalised patients with COVID-19 had fewer problems of constipation and hard stools at 12 months after acute infection. Patients with COVID-19 had significantly higher rates of IBS than controls. Trial registration number: NCT04691895.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
